


ESMO Asia 2022 Industry Satellite Symposium

Optimizing treatment outcomes in advanced urothelial carcinoma and metastatic renal cell carcinoma

This faculty-led symposium is organised and funded by the Merck-Pfizer Alliance. ©2022 All rights reserved.

Saturday 3 December 2022, 12:45–14:15 SGT
Hall 407, Level 4, Suntec Singapore Convention & Exhibition Centre, Singapore
Available on demand until 7 December



Masatoshi Eto

Kyushu University
Fukuoka, Japan



Lisa Pickering

Royal Marsden
London, UK



Howard Gurney

Macquarie University
New South Wales, Australia



Enrique Grande

MD Anderson Cancer
Center Madrid, Spain

Faculty-Led Programme

DURATION	TITLE	SPEAKERS
5 mins	Welcome and introduction of faculty, agenda overview	Masatoshi Eto
25 mins	Practical treatment considerations in an evolving landscape for metastatic renal cell carcinoma	Lisa Pickering
20 mins	Building on a standard of care in advanced urothelial carcinoma treatment	Howard Gurney
20 mins	Sequencing anticancer agents across lines of therapy in advanced urothelial carcinoma	Enrique Grande
15 mins	Q&A with all faculty	All faculty
5 mins	Closing remarks	Masatoshi Eto

Lunch bags will be provided for in-person attendees

Presentations of this event are intended for educational purposes only for the use of healthcare professionals to whom they are addressed and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the third party speakers individually and are not the opinion or position of the Merck-Pfizer Alliance. It is essential that you always refer to product information applicable in the country where you prescribe the products. Further distribution of this invitation or any information to be provided in the event is prohibited.